GT BIOPHARMA, INC. Lessee, Operating Lease, Liability, to be Paid, Year One
GT BIOPHARMA, INC. (GTBP) had Lessee, Operating Lease, Liability, to be Paid, Year One of $60.00 million as of 2023-12-31, per its 10-K filed 2024-03-26.
Discontinued › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2024-03-26
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $60.00M.
- 2023-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $2.00K.
- 2023-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $3.00K.
- 2023-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $34.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2023-12-31 | $60.00M 10-K · filed 2024-03-26 |
| 2023-09-30 | $2.00K 10-Q · filed 2023-11-01 |
| 2023-06-30 | $3.00K 10-Q · filed 2023-08-07 |
| 2023-03-31 | $34.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $122.00K 10-K · filed 2023-03-30 |
| 2022-09-30 | $94.00M 10-Q · filed 2022-10-31 |
| 2022-06-30 | $121.00M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $122.00M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |